5:23 PM
 | 
May 02, 2013
 |  BC Extra  |  Financial News

Teva submits thrice-weekly Copaxone sNDA, beats Street

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) disclosed on a conference call to discuss its 1Q13 earnings that it submitted an sNDA to FDA in March to add a thrice-weekly 40 mg dose of

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >